Abstract
Nektar Therapeutics will release quarterly results on November 12, 2026 Post-Mkt; consensus points to revenue of 10.27 million US dollars and adjusted EPS of -2.07, with focus on royalty and collaboration revenue pacing, expenses, and the rezpegaldesleukin program’s progress.Market Forecast
Consensus for this quarter anticipates revenue of 10.27 million US dollars, up 2.24% year over year, with adjusted EPS at -2.07 reflecting a 22.91% YoY improvement and EBIT at -67.48 million US dollars implying a -72.34% YoY change; gross margin is expected to remain around 100.00% given the royalty-driven mix, while no explicit net profit margin forecast is available. The company’s main revenue stream remains non-cash royalties linked to the sale of future royalties, with a steady outlook tied to milestone and royalty timing; the most promising driver is the rezpegaldesleukin program, which is not yet commercial and thus contributed no revenue last quarter, keeping YoY revenue contribution at 0.Last Quarter Review
For the prior quarter, Nektar Therapeutics reported revenue of 10.13 million US dollars, a gross profit margin of 100.00%, GAAP net loss attributable to the parent company of 40.62 million US dollars, net profit margin not disclosed, and adjusted EPS of -1.23, representing a 58.31% YoY improvement; quarter-on-quarter change in net profit was 9.54%. The quarter’s EPS loss narrowed relative to expectations, aided by stringent cost control and predictable royalty-related revenue. Main business revenue came entirely from non-cash royalties related to the sale of future royalties at 10.13 million US dollars, down 9.34% year over year, underscoring the dependence on collaboration and royalty accounting schedules.Current Quarter Outlook
Main revenue and expense dynamics this quarter
Revenue this quarter is projected at 10.27 million US dollars, a 2.24% increase from the year-ago period, anchored by non-cash royalty inflows that carry near-100.00% gross margin characteristics. The margin structure provides strong top-line-to-gross-profit conversion, but the overall P&L remains driven by operating expenses, with EBIT projected at -67.48 million US dollars and an implied year-over-year change of -72.34%. In this setup, the loss trajectory primarily reflects the cadence of late-stage clinical spending and G&A tied to portfolio advancement and corporate activity, rather than revenue volatility. Investors should pay close attention to the sequencing of collaboration milestones and any updates on the timing of recognizing royalty-related items, which can tilt the reported top line slightly above or below consensus without materially changing the medium-term narrative. Management’s ability to modulate operating spend in line with late-stage trial needs will be essential to translating the expected 22.91% YoY improvement in adjusted EPS into tangible progress toward loss containment.Rezpegaldesleukin development as the most promising driver
The rezpegaldesleukin program remains the company’s most significant value lever and the focal point for medium-term optionality, even though it is not yet revenue-generating. Recent clinical communications indicate early molecular and clinical signals in atopic dermatitis, and the company has embarked on a broad late-stage development footprint in that indication with multiple large global studies. While these trials do not contribute revenue at this stage, the sequencing, enrollment momentum, and any interim readouts or operational updates can influence sentiment and cost expectations, thereby affecting the EBIT profile in the near term. Because rezpegaldesleukin contributed no revenue in the last quarter and remains pre-commercial, its YoY revenue contribution remains 0, but the program’s progress is nonetheless a key swing factor that can influence the stock through changes in perceived probability of success and potential timeline clarity.Key factors most likely to influence the stock this quarter
A recent jury verdict awarding damages in a dispute with a former collaboration partner has introduced a potential non-operating catalyst, although timing and recognition remain subject to post-trial procedures and possible appeal. Investors will look for any commentary on how and when such outcomes might influence reported results, but the near-term P&L is still expected to be shaped primarily by operating expenses rather than one-off items. The company’s funding position has been reinforced through capital markets activity, with recent commentary suggesting cash levels around 300.00 million US dollars; this bolsters runway for the late-stage program set-up and reduces near-term financing concerns. With EBIT expected at -67.48 million US dollars and adjusted EPS at -2.07, the balance of the quarter’s narrative hinges on the discipline of spend, clarity on trial execution, and the cadence of collaboration and royalty inflows. Volatility may arise from updates to clinical timelines, readout planning, or any changes to cost pacing, and the market will parse guidance language for signals on expense ramp and capital allocation sequencing across atopic dermatitis and other target indications.Analyst Opinions
Across the past six months, the balance of published institutional views is skewed bullish, with approximately 67% of opinions in the positive camp versus 33% that are neutral or cautious. The majority expects modest revenue progression this quarter, a gross margin near 100.00% due to the royalty mix, and a gradual narrowing of per-share losses consistent with the -2.07 adjusted EPS forecast. Within this majority, several well-known institutions have articulated constructive views anchored on clinical momentum and improving financial visibility. B. Riley Securities has reiterated a Buy rating with a stated price target of 150.00 US dollars, highlighting the late-stage atopic dermatitis program as the key value driver and pointing to the company’s strengthened balance sheet as supportive of execution. Canaccord Genuity also maintained a Buy rating with a 153.00 US dollars price objective, framing this quarter’s setup as primarily an expense-control and trial-cadence story while underscoring that the royalty-derived gross margin profile offers resilience to the top-line. William Blair reiterated an Outperform view, emphasizing that recent clinical signals in atopic dermatitis, along with the broadening development plan, have improved the long-term optionality for the asset and justified continued investor attention through the current expense investment cycle. Leerink Partners initiated with an Outperform rating and a 130.00 US dollars target, citing the scope and scale of the ongoing late-stage program as a cornerstone and stating that the path to de-risking is increasingly defined despite the timeline required for registrational evidence.Collectively, the bullish camp’s reasoning converges on a few common points. First, the expected revenue of 10.27 million US dollars and a gross margin near 100.00% underline that quarterly top-line fluctuations are secondary to the expense curve and clinical execution, which the majority believes management is positioning to manage. Second, the projected 22.91% YoY improvement in adjusted EPS signals directional progress even if absolute losses remain significant, suggesting operational discipline during a late-stage investment phase. Third, the rezpegaldesleukin program’s multi-study, multi-indication footprint gives the company several shots on goal, and the early atopic dermatitis signals communicated in recent months support the premise that the biology can translate into clinically meaningful outcomes as trials scale. The bullish view does not ignore risks around timelines, trial outcomes, or expense pacing; rather, it argues that the current valuation-implied probabilities allow for upside if the program continues to hit operational milestones and if expense management maintains the observed trajectory. On balance, the majority of analysts anticipate that this quarter’s print will be characterized by modest revenue growth, a consistent gross margin profile, and a loss line tracking broadly to expectations, with management commentary providing the more salient readthrough for the path into 2027 and beyond.
Comments